@supertramp I think you are mistaken. From the inclusion criteria in the trial I quoted (No NCT01041404):
"Inoperable locally advanced, recurrent, and/or metastatic cancer of the stomach or gastro-esophageal junction"
The trial which you quote was designed to test two different dosing regimens for Herceptin. It was not terminated because Herceptin was ineffective. Indeed, of the combined 65 patients that were analysed in both groups an ORR of >50% was observed.
@supertramp I think you are mistaken. From the inclusion...
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $386.7M | |||
| Open | High | Low | Value | Volume |
| 3.8¢ | 3.8¢ | 3.7¢ | $270.7K | 7.251M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 949810 | 3.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.8¢ | 2277658 | 11 |
View Market Depth
| Last trade - 16.10pm 26/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |
